<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cannabidiol (CBD) has beneficial effects in disorders as wide ranging as <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:e sem="disease" ids="C0020179" disease_type="Disease or Syndrome" abbrv="HD">Huntington's disease</z:e>, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:hpo ids='HP_0002583'>colitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Accumulating evidence now also suggests that CBD is beneficial in the cardiovascular system </plain></SENT>
<SENT sid="2" pm="."><plain>CBD has direct actions on isolated arteries, causing both <z:hpo ids='HP_0011009'>acute</z:hpo> and time-dependent vasorelaxation </plain></SENT>
<SENT sid="3" pm="."><plain>In vitro incubation with CBD enhances the vasorelaxant responses in animal models of impaired endothelium-dependent vasorelaxation </plain></SENT>
<SENT sid="4" pm="."><plain>CBD protects against the vascular damage caused by a high <z:chebi fb="105" ids="17234">glucose</z:chebi> environment, <z:mp ids='MP_0001845'>inflammation</z:mp>, or the induction of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in animal models, and reduces the vascular hyperpermeability associated with such environments </plain></SENT>
<SENT sid="5" pm="."><plain>A common theme throughout these studies is the anti-inflammatory and anti-oxidant effect of CBD </plain></SENT>
<SENT sid="6" pm="."><plain>In the heart, in vivo CBD treatment protects against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-reperfusion damage, or against <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> associated with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Similarly, in a different model of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-reperfusion, CBD has been shown to reduce <z:mpath ids='MPATH_124'>infarct</z:mpath> size and increase blood flow in animal models of <z:hpo ids='HP_0001297'>stroke</z:hpo>, sensitive to <z:chebi fb="0" ids="28790">5HT</z:chebi>(1A) receptor antagonism </plain></SENT>
<SENT sid="8" pm="."><plain>Although <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0011010'>chronic</z:hpo> CBD treatment seems to have little effect on haemodynamics, CBD reduces the cardiovascular response to models of stress, applied either systemically or intracranially, inhibited by a <z:chebi fb="0" ids="28790">5HT</z:chebi>(1A) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>In blood, CBD influences the survival and <z:hpo ids='HP_0011420'>death</z:hpo> of white blood cells, white blood cell migration and platelet aggregation </plain></SENT>
<SENT sid="10" pm="."><plain>Taken together, this preclinical data appears to support a positive role for CBD treatment in the heart, and in peripheral and cerebral vasculature </plain></SENT>
<SENT sid="11" pm="."><plain>However, further work is required to strengthen this hypothesis, establish mechanisms of action and whether similar responses to CBD would be observed in humans. © 2012 The Authors </plain></SENT>
<SENT sid="12" pm="."><plain>British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society </plain></SENT>
</text></document>